Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6006612 | 0.73 | KDM4E (0.50) | L3MBTL1LMNAGAAKMT2ASMN1; SMN2 | |
| SCHEMBL1295044 | 0.73 | ALDH1A1 (0.64) | L3MBTL1LMNAGAAKMT2APOLB | |
| SCHEMBL5838878 | 0.72 | SMN1; SMN2 (0.44) | L3MBTL1LMNAGAAKMT2APOLB | |
| SCHEMBL6677698 | 0.72 | NOTUM (0.57) | L3MBTL1LMNAGAAKMT2APOLB | |
| SCHEMBL19410709 | 0.71 | KDM4E (0.50) | L3MBTL1LMNAKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL31373871 | 0.71 | KDM4E (0.59) | L3MBTL1LMNAGAAKMT2ASMN1; SMN2 | |
| SCHEMBL28253031 | 0.70 | KDM4E (0.51) | L3MBTL1LMNAGAAKMT2ASMN1; SMN2 | |
| SCHEMBL28246630 | 0.70 | SMN1; SMN2 (0.51) | L3MBTL1LMNAGAAKMT2ASMN1; SMN2 | |
| SCHEMBL23771943 | 0.70 | KDM4E (0.51) | L3MBTL1LMNAGAAKMT2ASMN1; SMN2 | |
| SCHEMBL29814717 | 0.70 | KDM4E (0.51) | L3MBTL1LMNAGAAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278982-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL YANG-MING UNIVERSITY (TW) | 2016-03-08 | — | — | US | disclosed |
| US-20130252953-A1 | Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells | NATIONAL YANG-MING UNIVERSITY (TW) | 2013-09-26 | — | — | US | disclosed |
| WO-2012072019-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | CHANG ZEE-FEN (CN) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252953-A1 | Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells | DTYMK, TYMP, DCK | L3MBTL1 579/4885LMNA 2937/4885GAA 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.